Abeona Therapeutics, Inc. Forecast, price target & analysts
Abeona Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Abeona Therapeutics, Inc. Classifications & Recommendation
Abeona Therapeutics, Inc. Price Target
| Target Price | $17.34 |
| Price | $5.01 |
| Potential |
246.11%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Abeona Therapeutics, Inc. 2027 .
The average Abeona Therapeutics, Inc. target price is $17.34.
This is
246.11%
register free of charge
$29.40
486.83%
register free of charge
$14.14
182.24%
register free of charge
|
|
| A rating was issued by 12 analysts: 11 Analysts recommend Abeona Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Abeona Therapeutics, Inc. stock has an average upside potential 2027 of
246.11%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 5.82 | 55.42 |
| 852.30% | ||
| Net Margin | 1,223.02% | -97.42% |
| 107.97% |
9 Analysts have issued a sales forecast Abeona Therapeutics, Inc. 2026 . The average Abeona Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
10 Abeona Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Abeona Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.08 | -0.94 |
| 169.68% | 187.04% | |
| P/E | negative | |
| EV/Sales | 2.79 |
10 Analysts have issued a Abeona Therapeutics, Inc. forecast for earnings per share. The average Abeona Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Abeona Therapeutics, Inc....
Current Abeona Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 18 2026 |
| Roth Capital |
Locked
➜
Locked
|
Locked | Sep 17 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 28 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 10 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 18 2026 |
|
Locked
Roth Capital:
Locked
➜
Locked
|
Sep 17 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 28 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 10 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
